Black Diamond Therapeutics Inc. Common Stock (BDTX)

FairStock Score: 78/100 — HIGH CONVICTION

Key Financials

Strengths

• Generates $13 million in annual free cash flow (7.3% yield on market cap)
• High return on equity of 22.9% demonstrating efficient capital deployment
• Conservative balance sheet with debt-to-equity of just 0.17, providing financial flexibility
• FairStock composite score of 78/100 places it in the top tier across value, quality, and momentum factors

Concerns

• Currently unprofitable—sustained losses could lead to dilutive capital raises or balance sheet deterioration
• Weak Piotroski F-Score of 1/9 suggests deteriorating financial quality across multiple dimensions
• Altman Z-Score of 1.7 places it in the financial distress zone—elevated bankruptcy risk

AI Analysis

Black Diamond Therapeutics Inc. Common Stock is a micro-cap healthcare company valued at $179 million. Revenue stands at $70 million, though the company is currently unprofitable. From a quality standpoint, Black shows weak Piotroski F-Score of 1/9 signaling deteriorating fundamentals and distressed Altman Z-Score of 1.7 warrants caution. On valuation, the stock is deeply undervalued on a P/E basis at 8.0x, with a modest 25% margin of safety vs Graham Number. Growth dynamics show profit growth of 5.4%. Our composite FairStock Score of 78/100 reflects strong fundamentals overall. This combination of reasonable valuation, solid returns, and conservative leverage makes it worth a closer look for value-oriented portfolios.

Bull Case

The market underappreciates Black's consistent 23% ROE at just 8x earnings—a re-rating toward sector peers could unlock 30-50% upside. With $13 million in annual free cash flow (7.3% yield), management has ample capital for buybacks, dividends, or accretive acquisitions.

Bear Case

Without a clear path to profitability, continued cash burn forces either dilutive equity raises or debt accumulation that destroys shareholder value. Regulatory changes, input cost inflation, or demand normalization represent underappreciated risks that could materially impact forward estimates.

Data from SEC filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer